Literature DB >> 871015

Fate of prostaglandins E(1) and A(1) in the human pulmonary circulation.

G L Hammond, L H Cronau, D Whittaker, C N Gillis.   

Abstract

It is recognized that the lung extracts norepinephrine and 5-hydroxytryptamine from the pulmonary circulation and that this process is affected by cardiopulmonary bypass. Since alterations in the lung's processing of vasoactive substances may be a mechanism of pulmonary injury sustained during operation, we investigated the lung's ability to extract or metabolize prostaglandin A1 (ga1) and prostaglandin E1 (PGE 1). Sixteen patients undergoing cardiac surgery were studied. In five patients, just before going on bypass, a 10 ml of blood was withdrawn at a constant rate, simultaneously from the pulmonary artery and left atrium. In 11 patients, 3H-PGE1 was injected just prior to bypass and, in five of these, again after coming off bypass. Extraction was calculated from tritium activity in the samples. Metabolites were quantitated by thin-layer chromatography after being identified by marker compounds run simultaneously in each chromatogram. The pulmonary extraction of PGA1 was 11.3 +/- 2.3% and there were no detectable metabolites in left atrial blood. Before bypass the extraction of PGE1 was 42.3 +/- 14.3% and after bypass 24.8 +/- 10.0% (P less than 0.005; Student's paired t test). PGE1 was extensively metabolized with 79.7 +/- 7.1% of total radioactivity appearing in the left atrium as metabolites before bypass and 89.1 +/- 2.0% appearing after bypass. This study indicates that PGA(1) is not metabolized by the lung and is only slightly extracted. On the other hand, PGE(1) is extensively extracted and metabolized. While the rate of metabolism is not significantly affected by cardiopulmonary bypass, the extractiom before bypass was significantly greater than after bypass.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 871015

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

Review 1.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

2.  Expression of gastric antisecretory and prostaglandin E receptor binding activity of misoprostol by misoprostol free acid.

Authors:  B S Tsai; L K Kessler; J Stolzenbach; G Schoenhard; R F Bauer
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

Review 3.  Measurement of endothelial metabolic functions in vivo.

Authors:  C N Gillis
Journal:  Ann Biomed Eng       Date:  1987       Impact factor: 3.934

4.  Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

5.  Prostaglandin therapy in severe limb ischemia.

Authors:  B J Pardy; H H Eastcott
Journal:  World J Surg       Date:  1983-05       Impact factor: 3.352

Review 6.  The biochemical properties of the pulmonary circulation.

Authors:  J A Pang; D M Geddes
Journal:  Lung       Date:  1981       Impact factor: 2.584

Review 7.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

8.  Prostaglandin E1 vasospastic disease and thermography.

Authors:  V Kyle; G Parr; R Salisbury; P P Thomas; B Hazleman
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

9.  Endogenous prostaglandins and gastric secretion in the cat.

Authors:  R Baker; B M Jaffe; J D Reed; B Shaw; C W Venables
Journal:  J Physiol       Date:  1978-05       Impact factor: 5.182

Review 10.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.